Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 5/20 | 0.35 |
| ▸ | CETP | P11597 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 2/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359839 | 1.00 | ADORA2A (0.36) | ADORA2ALMNAHTTNPSR1TP53 | |
| SCHEMBL12741933 | 0.85 | BACE1 (0.42) | BACE1 | |
| SCHEMBL4368964 | 0.84 | ROCK2 (0.37) | LMNABACE1ROCK2MAPK1LIPE | |
| SCHEMBL4368961 | 0.84 | ROCK2 (0.37) | LMNABACE1ROCK2MAPK1LIPE | |
| SCHEMBL5311579 | 0.83 | LMNA (0.34) | ADORA2ALMNAHTTNPSR1TP53 | |
| SCHEMBL5311580 | 0.83 | LMNA (0.34) | ADORA2ALMNAHTTNPSR1TP53 | |
| SCHEMBL13675397 | 0.81 | BACE1 (0.39) | BACE1 | |
| SCHEMBL8293905 | 0.81 | BACE1 (0.39) | BACE1 | |
| SCHEMBL8292925 | 0.81 | BACE1 (0.39) | BACE1 | |
| SCHEMBL12742772 | 0.81 | BACE1 (0.39) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | ADORA2A 3385/4885LMNA 1677/4885HTT 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.